Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation Review

   

Authors:	O’Reilly, R. J.; Prockop, S.; Oved, J. H.
Review Title:	Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation
Abstract:	EBV+ lymphomas constitute a significant cause of morbidity and mortality in recipients of allogeneic hematopoietic cell (HCT) and solid organ transplants (SOT). Phase I and II trials have shown that in HCT recipients, adoptive transfer of EBV-specific T-cells from the HCT donor can safely induce durable remissions of EBV+ lymphomas including 70->90% of patients who have failed to respond to treatment with Rituximab. More recently, EBV-specific T-cells generated from allogeneic 3rd party donors have also been shown to induce durable remission of EBV+ lymphomas in Rituximab refractory HCT and SOT recipients. In this review, we compare results of phase I and II trials of 3rd party and donor derived EBV-specific T-cells. We focus on the attributes and limitations of each product in terms of access, safety, responses achieved and durability. The limited data available regarding donor and host factors contributing to T cell persistence is also described. We examine factors contributing to treatment failures and approaches to prevent or salvage relapse. Lastly, we summarize strategies to further improve results for virus-specific immunotherapies for post-transplant EBV lymphomas. Copyright © 2024 O’Reilly, Prockop and Oved.
Keywords:	treatment failure; clinical feature; mortality; review; gemcitabine; chemotherapy; rituximab; cd8+ t lymphocyte; allele; microrna; morbidity; in vivo study; in vitro study; transplantation; immunotherapy; gamma interferon; immunogenicity; cd4+ t lymphocyte; lymphoma; graft versus host reaction; hematopoietic cell; remission; allogeneic hematopoietic stem cell transplantation; umbilical cord blood; cd3+ t lymphocyte; graft recipient; epstein barr virus; antiviral activity; t-cells; phase 2 clinical trial (topic); organ donor; posttransplant lymphoproliferative disease; phase 1 clinical trial (topic); neomycin; virus cell interaction; hla antibody; cytokine release syndrome; refractory disease; lymphoproliferative disorder; human; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; ebv-ctls; epstein-barr virus (ebv); third party
Journal Title:	Frontiers in Immunology
Volume:	14
ISSN:	1664-3224
Publisher:	Frontiers Media S.A.
Date Published:	2023-01-01
Start Page:	1290059
Language:	English
DOI:	10.3389/fimmu.2023.1290059
PROVIDER:	scopus
PMCID:	PMC10808771
PUBMED:	38274824
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85182990535&doi=10.3389%2ffimmu.2023.1290059&partnerID=40&md5=163265bcf8741f2cb5970ba4955c8e52
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding MSK author is Richard J. O’Reilly -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/213053